@article{TEXTUAL,
      recid = {8416},
      author = {Sweiss, Nadera J. and Bo, Ronghai and Kapadia, Reena and  Manst, Deborah and Mahmood, Farzan and Adhikari, Tara and  Volkov, Suncica and Badaracco, Maria and Smaron, Mary and  Chang, Anthony and Baron, Joseph and Levine, Jerrold S.},
      title = {IgA Anti-β2-Glycoprotein I Autoantibodies Are Associated  with an Increased Risk of Thromboembolic Events in Patients  with Systemic Lupus Erythematosus},
      journal = {PLOS ONE},
      address = {2010-08-19},
      number = {TEXTUAL},
      abstract = {&lt;p&gt;Background: The clinical utility of testing for  antiphospholipid antibodies (aPL) of IgA isotype remains  controversial.&lt;/p&gt;&lt;p&gt;Methodology/Principal Findings: To  address this issue, we reasoned that if IgA aPL contribute  to the clinical manifestations of the antiphospholipid  syndrome, then an association with thromboembolic events  should manifest in patients whose only aPL is of IgA  isotype. We performed a retrospective chart review of 56  patients (31 with systemic lupus erythematosus [SLE] and 25  without SLE) whose only positive aPL was IgA  anti-β2-glycoprotein I (isolated IgA anti-β2GPI) and  compared their clinical features with 56 individually  matched control patients without any aPL. Patients with  isolated IgA anti-β2GPI had a significantly increased  number of thromboembolic events, as compared to controls.  When patients were stratified into those with and without  SLE, the association between isolated IgA anti-β2GPI and  thromboembolic events persisted for patients with SLE, but  was lost for those without SLE. Titers of IgA anti-β2GPI  were significantly higher in SLE patients who suffered a  thromboembolic event. Among patients with isolated IgA  anti-β2GPI, there was an increased prevalence of diseases  or morbidities involving organs of mucosal immunity (i.e.,  gastrointestinal system, pulmonary system, and  skin).&lt;/p&gt;&lt;p&gt;Conclusions/Significance: The presence of  isolated IgA anti-β2GPI is associated with an increased  risk of thromboembolic events, especially among patients  with SLE. IgA anti-β2GPI is associated with an increased  prevalence of morbidities involving organs of mucosal  immunity.&lt;/p&gt;},
      url = {http://knowledge.uchicago.edu/record/8416},
}